Phase 1 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People diagnosed with relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL) who have already received 2 standard lines of treatment, and whose doctor believes they need further treatment.
• People diagnosed with other relapsed or refractory B-cell non-Hodgkin's lymphomas (such as CLL, SLL, MCL, MZL, or Waldenström's macroglobulinaemia) who have already received 1 standard line of treatment, and whose doctor believes they need further treatment.
• People with adequate blood cell counts, liver function, and kidney function (confirm with trial site for specific thresholds).
• People who are able to swallow and take the study drug by mouth, and who are willing to attend required examinations.
• People of reproductive potential who are willing to use reliable contraception throughout the trial — this applies to both men and women who have not yet reached menopause or had surgery to prevent pregnancy.

Who may not be able to join:

• People diagnosed with Burkitt lymphoma, Burkitt-like lymphoma, lymphoblastic lymphoma or leukemia, or lymphoma that developed after an organ transplant.
• People who have had another cancer in the past 3 years, unless it was a fully treated skin cancer (basal or squamous cell), early-stage cervical cancer, or early-stage breast cancer.
• People who have received anti-cancer treatments — including chemotherapy, targeted therapy, biological therapy, immunotherapy, or any other experimental treatment — within 4 weeks or 5 half-lives before starting the study drug, whichever is longer.
• People who have had major surgery, serious physical trauma, or radiotherapy within 4 weeks before starting the study drug.
• People who have taken steroids or herbal medicines for cancer treatment purposes within 2 weeks before starting the study drug.
• People who have taken strong or moderate CYP3A inhibitors or inducers, or any medications known to affect heart rhythm in a specific way (QTc prolongation), within 2 weeks before starting the study drug (confirm specific medications with trial site).
• People with certain hard-to-control health conditions, including HIV, active Hepatitis B or C, syphilis, or active bacterial or fungal infections.
• People whose lymphoma has spread to the central nervous system with clear symptoms.
• People with certain immune-related blood conditions, including autoimmune haemolytic anaemia or immune thrombocytopenic purpura.
• People with gastrointestinal conditions that could seriously affect how the study drug is absorbed by the body.
• People who are unable to tolerate urine collection, blood draws, lymph node biopsy, or bone marrow sampling.

Important: Always verify eligibility with the trial site directly before applying.